In the pursuit of groundbreaking targeted cancer therapies, biotechnology company Immunome Inc. has chosen Arrayjet’s ArrayPlex discovery platform to bolster its in-house high-throughput screening tools. Through this collaboration, Immunome aims to accelerate the discovery and development of first-in-class and best-in-class cancer therapies. Arrayjet, a leading provider of inkjet liquid-handling solutions, is making its proprietary multi-layer microarray platform available to Immunome and other screening customers through its CRO/CMO services.
Expanding High-Throughput Screening Capabilities:Immunome’s decision to utilize Arrayjet’s ArrayPlex platform illustrates the increasing significance of high-throughput screening in the field of cancer therapy discovery. High-throughput screening allows researchers to rapidly test large libraries of compounds against specific disease targets, enabling the identification of potential therapeutic candidates. By expanding their in-house screening tools with ArrayPlex, Immunome aims to enhance their capacity to identify and validate targeted cancer therapies efficiently.
ArrayPlex: A Versatile and Powerful Platform:The ArrayPlex platform offers Immunome unprecedented flexibility in its screening endeavors. Its proprietary multi-layer microarray technology allows for the precise deposition of minute volumes of reagents, enabling high-density, high-throughput screening. This advanced liquid-handling platform ensures accuracy and reproducibility while minimizing sample consumption, thereby saving both time and resources. Furthermore, ArrayPlex offers customizable options that can cater to Immunome’s specific screening requirements, allowing for efficient adaptation to diverse experimental needs.
Collaborative Partnership for Accelerated Cancer Drug Discovery:The collaboration between Immunome and Arrayjet marks an important milestone in the advancement of cancer drug discovery. By combining Immunome’s expertise in immunotherapy and targeted cancer treatments with Arrayjet’s cutting-edge liquid-handling technology, the partners aim to accelerate the identification and development of novel cancer therapies. Arrayjet’s CRO/CMO services, through which the ArrayPlex platform is accessible to screening customers, further promote collaboration and open new avenues for innovative drug discovery initiatives.
Leveraging Arrayjet’s Expertise:Arrayjet’s extensive experience in providing inkjet liquid-handling solutions positions them as a trusted partner for Immunome’s drug discovery efforts. Arrayjet has a proven track record of delivering robust and reliable microarray platforms that have been adopted by numerous organizations involved in drug discovery and research. Their commitment to developing state-of-the-art technology tailored to the specific needs of their customers makes them an ideal collaborator for Immunome’s cancer therapy development.
Conclusion:Arrayjet’s ArrayPlex platform brings tremendous value to Immunome’s quest for targeted cancer therapies. By incorporating this innovative high-throughput screening tool, Immunome gains access to a versatile and reliable platform capable of accelerating the identification and validation of potential candidates. The partnership between Immunome and Arrayjet exemplifies the industry’s commitment to collaboration and technological advancements in the pursuit of improved cancer treatments. As this partnership continues to evolve, we can expect additional breakthroughs in the field of targeted cancer therapy discovery.
Comments